The 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium
Fourth Head-to-Head Comparison Reveals Important Clinical Distinctions Between Oncotype DX, the Only Test Demonstrated to Predict Chemotherapy Benefit, and Tests Limited to Breast Cancer Prognosis
Conference Marks 10th Anniversary of First Oncotype DX Validation Study, Representing a Decade of Progress in Eliminating 'One-Size-Fits-All' Approach to Breast Cancer Treatment
As an investor/trader I always care, and don't like surprises. My question was part of the decision as to whether to buy the dip, which I did. Relax Hobo, Giggle must be getting under your skin.
Guess again clown boy.Just go back to you (RS) 1.50 dollar stock INSM.After more than a decade? are you close to being even? I doubt it.
RE: "Any idea on why the sell off?"
If you're an investor....who cares?
If you're a trader, you should have stopped yourself out by now.
GHDX is a low beta stock and generally does acts better in weak markets so today's action is a little out of character...perhaps NSTG's news of Prosigna adoption is having an impact?
and speaking of investing in the future, GHI today participated in the $40MM fund raising effort by InVitae (~20% owned by GHI) Look up InVitae if you are not familiar. Founded by and run by GHI founder Randy Scott, they are working on a single assay that will include everything in the over 3000 assays currently out there....for about $1000 per test.
stock price waivers from day to day and week to week but follow the science.....this stock is going much much higher in the future....great company for building long term wealth.
From Luke Timmerman last week:
Genomic Health. The Redwood City, CA-based company (NASDAQ: GHDX) is widely admired in diagnostics because it proved to skeptical insurers that diagnostics aren’t just cheap commodities anymore—they provide information about health that’s quite valuable. Genomic Health has continued to thrive and grow under two CEOs—Randy Scott and Kim Popovits. It is now rolling out new iterations of its original OncotypeDx product that predict the risk of recurrence for patients with prostate and colon cancer, proving it’s not a one-hit wonder in breast cancer. By showing the way in molecular diagnostics, Genomic Health has inspired other entrepreneurs to think big about how new instruments can be used to better predict and prevent disease before doctors have to turn to high-priced and often-toxic therapies. The company could be highly profitable tomorrow if it wanted to be, but instead it chooses to get by on low margins while continuing to invest in the future. It’s a sure sign of a company with a view toward long-term excellence.
Well thank you Johnny. How much did I make today? Giggle Giggle
Sentiment: Strong Sell
Too easy of a call. Simply Amazin! Giggle Giggle
Sentiment: Strong Sell
improvement in product sales came mainly on the back of double-digit growth in test volume across all areas of the company’s business. The increased adoption of the prostate cancer test and the approval of Oncotype DX by National Institute for Health and Care Excellence’s (NICE) also aided the successful results. NICE recognized Oncotype DX as the sole test to predict recommended chemotherapy benefits for patients with early-stage, hormone receptor-positive, invasive breast
During the reported quarter, international product revenues grew 25% year over year to $10.1 million. Genomic provided 21,790 Oncotype DX test results, up 21%
from the year-ago quarter.
Gross profit increased 11.3% year over year to $55.2 million. However, the recent prostate cancer test launch and impact of sequestration led to a contraction of 93
basis points (bps) in gross margin, which stood at 83.7% in the quarter. On the other hand, with a 19.3% rise in operating expenses to $54.7 million, the company
incurred operating profit of a nominal $463 million, down a significant 87.5% from the prior-year quarter. The rise in operating expenses originated from higher
research and development (up 20.0% to $14.7 million), selling and marketing (up 20.8% to $26.0 million), and general and administrative (up 15.7% to $14.0
Genomic Health exited the third quarter with cash and cash equivalents, and short-term marketable securities of $114.0 million, up from $99.1 million at the end of
NICE in the U.K. issued final guidance recommending Oncotype DX as the only multi-gene breast cancer test to guide chemotherapy treatment decisions. Moreover,
Genomic health established node-positive and ductal carcinoma in situ (DCIS) coverage for approximately 1.3 million U.S. lives through a contract with a large Blue Cross Blue Shield state plan.
flatlander.great strategy (covered calls ) unless they get taken out.Consolidation in the industry has accelerated.
Have fun while it lasts. One day you'll wake up to a $65 open and be wiped out.
I followed the Baker Bros and loaded up in the mid 20's. However, there have been several ups and downs since I bought. The downdrafts have been severe enough to make me kick myself for not harvesting some gains by taking something off the table. I'm a strong believer that the prostate test will be a game changer. The Cleveland clinic testing and support bodes well. However, the value will have to be confirmed in several peer reviewed medical journals before there will be really widespread acceptance. Till then I think the sales ramp will be steady in the low double digit range. Eventually insurers will become big backers since the test will save millions of unnecessary procedures. This and geographic expansion will fuel many years of growth I might want to consider a pair trade where I might eventually short the makers/operators of proton treatment for prostate cancer. Competition can always change the landscape but for now GHDX looks to be well situated. I've decided to maintain a strong core holding and write covered calls on about 25% of my holdings when the share price reaches lofty periods.